Trading Ideas

Shares in AstraZeneca (AZN) dropped 3.5% even after early-stage human trial data from its Covid-19 vaccine candidate showed “robust” immune responses.The stock declined to $58.96 in afternoon market trading. Interim data results from the ongoing Phase I/II trial of the potential coronavirus vaccine, also known as AZD1222, which AstraZeneca is developing with Oxford University, showed “strong” antibody and immune T-cell responses.“While there is more work to be done, today’s data increases our confidence that the vaccine will work and allows us to continue our plans to manufacture the vaccine at scale for broad and equitable access around the world,” said …read more […]

Over the last few years – and certainly since the March crash – tech stocks have been on a tear. However, veteran tech giant IBM (IBM) has found it difficult to keep up, and has lagged behind the whole market. Yet, with F2Q earnings due today after market close, could sentiment be changing?With the Street calling for a year-over-year drop of 35% to revenue of $17.7 billion and EPS to decline by 8% to $2.07, Merrill Lynch analyst Wamsi Mohan argues the low expectations could provide IBM with a minor victory when it releases its quarterly statement this evening.Mohan said, …read more […]

Both calls and puts are being order up at an unusual rate today …read more […]

Columbia University’s Dr. Bernard Chang joins Yahoo Finance’s Zack Guzman to discus the recent coronavirus developments as cases surge in Florida and California. …read more […]

(Bloomberg) — Silver futures are latching on to gold’s rally, climbing above $20 an ounce to the highest since 2016 on rising haven demand and concerns about supply of the white metal.Gold and silver have surged this year as the coronavirus pandemic roiled the global economy, spurring sustained demand for havens even as some lockdowns were eased. The outbreak has yet to be brought under control in many countries including the U.S., bolstering the case for holding the metals.Silver, which just completed its best quarter since 2010, is getting an extra boost from concerns about supply and bets on increased …read more […]

The markets face two big risks amid the COVID-19 pandemic, says Tom Essaye, founder of the Sevens Report Research. …read more […]

(Bloomberg) — AstraZeneca Plc fell from a record high in New York trading after data for the company’s Covid-19 vaccine candidate, though promising, fueled concerns about whether it can match competitors.Bernstein analysts led by Ronny Gal said the vaccine, developed in partnership with the University of Oxford, showed early positive data, but the benefits didn’t appear to match the bar set by programs from Pfizer Inc. and BioNtech SE, as well as Moderna Inc.“In the competitive context they fail to impress,” Gal wrote.Exacerbating concerns, the Lancet medical journal publication came just an hour after Pfizer and BioNtech had announced early …read more […]

Convinced of Tesla Inc’s imminent meteoric rise, Orestis Palampougioukis, a Netherlands-based software developer, took out a 43,000 euro ($49,000) loan in early October to invest it all in the electric carmaker, which at the time was trading at around $230 a share. Since then, Palampougioukis’ bet has paid off as Tesla’s share price has increased more than six-fold, trading around $1,500 on Monday and surpassing every rival to become the world’s highest-valued automaker. “To me it didn’t feel like a bet because I studied what Tesla does very closely and it’s simply inevitable that it would …read more […]

If you want to know who really controls Exelixis, Inc. (NASDAQ:EXEL), then you’ll have to look at the makeup of its… …read more […]

Polen Capital Management recently released its Q2 2020 Investor Letter, a copy of which you can download here. During the second quarter of 2020, the Polen Global Growth Model Portfolio returned 20.58% gross of fees, while the MSCI All Country World Index was up 19.22%. You should check out Polen Capital’s top 5 stock picks […] …read more […]

Second quarter earnings season is upon us, and Wall Street watchers are focused on the results. Weighing in after looking at the initial results, investment firm RBC describes the earnings season as ‘pivotal.’ After the grim results in Q1, investors are hoping for better earnings in Q2, but are girding themselves for the possibility of downward revisions.But for now, at least, the results have been, in RBC words, ‘less bad than feared.’ The firm notes that 56% of the revisions to EPS estimates so far for 2020 and 2021 have been upward. It’s a welcome positive sign, especially considering indicators …read more […]

Yahoo Finance’s Adam Shapiro and Julie Hyman highlight Monday’s trending headlines. …read more […]

Yahoo Finance’s Adam Shapiro breaks down the latest stocks to watch. …read more […]

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […] …read more […]

U.S. energy giant Chevron Corp. (CVX) has entered into a definitive agreement to buy all of the outstanding shares of Noble Energy, Inc. (NBL) in an all-stock deal valued at $5 billion.Under the terms of the agreement, Noble Energy shareholders will receive 0.1191 shares of Chevron for each Noble Energy share. The transaction price of $10.38 per share represents a premium of about 7.5% to Noble’s Friday close. Upon deal closure, Noble shareholders will own about 3% of the combined company. The total enterprise value, including debt, of the transaction amounts to $13 billion.Noble shares rose 6% to $10.22 in …read more […]